Novo partners with Orbis, deepening investment in oral peptide drugs
Source ↗
👁 1
💬 0
The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.
Comments (0)